Substance

ID:886

Names and Identifiers
Brand Name
AlrheumunCapistenKefenidKetopronMenaminMeprofenOrugesicAlrheumatEpatecFastumLertusIso-KOruvailOscorelProfenidDexalOrudisOrudis KTToprecToprekActron
Synonyms
Ketoprofenm-Benzoylhydratropic acid
IUPAC name
2-(3-benzoylphenyl)propanoic acid
IUPAC Traditional name
ketoprofen
Registration numbers
CAS Number
PubChem CID
PubChem SID
Properties
Physical Property
Hydrophobicity(logP)
3.2
Solubility
51 mg/L
Molecule Details
Drug Groups
approved
Description
Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.
Indication
For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.
Pharmacology
Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.
Toxicity
LD50=62.4 mg/kg (rat, oral).

Symptoms of overdose include drowsiness, vomiting and abdominal pain.


Side effects are usually mild and mainly involved the GI tract. Most common adverse GI effect is dyspepsia (11% of patients). May cause nausea, diarrhea, abdominal pain, constipation and flatulence in greater than 3% of patients.

Affected Organisms
Humans and other mammals
Biotransformation
Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.
Absorption
Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.
Half Life
Conventional capsules: 1.1-4 hours

Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)

Protein Binding
99% bound, primarily to albumin
Elimination
In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.
Clearance
* Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]
* Oral-dose cl=6.8 +/- 1.8 L/h [Ketoprofen Extended-release capsules (1 × 200 mg)]
* 0.08 L/kg/h
* 0.7 L/kg/h [alcoholic cirrhosis patients]
References
• Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. [Pubmed]
• Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. [Pubmed]
Molecular Spectra
No Data Available
Click here to submit data
References
• Mazieres B: Topical ketoprofen patch. Drugs R D. 2005;6(6):337-44. Pubmed
• Kantor TG: Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy. 1986 May-Jun;6(3):93-103. Pubmed